PD-L1 Biomarker Testing Market to Grow with a CAGR of 7.88% through 2030

Advancements in AI-powered diagnostic tools for biomarker analysis and growing investments in precision medicine research, is expected to drive the Global PD-L1 Biomarker Testing Market growth in the forecast period, 2026-2030

According to TechSci Research report, “PD-L1 Biomarker Testing Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, the Global PD-L1 Biomarker Testing Market stood at USD 764.31 Million in 2024 and is expected to reach USD 1206.51 Million by 2030 with a CAGR of 7.88% during the forecast period. The Global PD-L1 Biomarker Testing Market has witnessed remarkable growth in recent years, driven by various factors that have transformed the landscape of cancer diagnosis and treatment. Programmed Death-Ligand 1 (PD-L1) biomarker testing has emerged as a crucial tool in the field of oncology, aiding clinicians in making informed decisions regarding immunotherapy treatment strategies. One of the primary drivers behind the growth of the PD-L1 biomarker testing market is the escalating global incidence of cancer. Cancer remains a major public health concern, and the demand for effective and targeted treatments is on the rise. PD-L1 testing helps identify patients who are likely to benefit from immune checkpoint inhibitor therapies, such as PD-1 and PD-L1 inhibitors, thereby enhancing the precision and efficacy of cancer treatment. Immunotherapy has revolutionized cancer treatment by harnessing the body's immune system to target and destroy cancer cells. PD-L1 biomarker testing is crucial in identifying patients who are suitable candidates for immunotherapy. The remarkable success of immune checkpoint inhibitors in various cancer types, including non-small cell lung cancer (NSCLC), melanoma, and bladder cancer, has led to increased demand for PD-L1 testing, as clinicians seek to optimize patient outcomes.

The era of personalized medicine is gaining momentum, with healthcare providers increasingly focusing on tailoring treatments to individual patients. PD-L1 biomarker testing is a prime example of this approach, as it helps identify patients who are most likely to respond positively to immunotherapy, sparing others from potentially ineffective and harsh treatments. This personalized approach not only improves patient outcomes but also reduces healthcare costs. Initially, PD-L1 testing was primarily associated with NSCLC. However, its applications have expanded to include various cancer types, such as breast cancer, gastric cancer, head and neck cancer, and more. This broader range of applications has contributed significantly to the market's growth, as it addresses the needs of a larger patient population.

Advances in diagnostic technologies have played a pivotal role in the growth of the PD-L1 biomarker testing market. Various testing methods, including immunohistochemistry (IHC), polymerase chain reaction (PCR), and next-generation sequencing (NGS), have become more precise, reliable, and accessible. These technological advancements have not only improved the accuracy of PD-L1 testing but have also made it more cost-effective.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global PD-L1 Biomarker Testing Market”

The Global PD-L1 Biomarker Testing Market is segmented into cancer type, assay kit type, end use, regional distribution, and company.

Based on the End Use, Research and Development emerged as the fastest growing segment in the Global PD-L1 Biomarker Testing Market during the forecast period. This is due to the increasing focus on precision oncology and immunotherapy advancements. Pharmaceutical and biotechnology companies, along with academic institutions, are heavily investing in biomarker research to enhance the efficacy of immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, for treating various cancers. The rise in clinical trials evaluating novel PD-L1 targeted therapies and companion diagnostics is driving the demand for biomarker testing in R&D settings. Government and private funding initiatives are further propelling research efforts. For instance, the National Cancer Institute (NCI) in the United States allocated substantial funding for cancer biomarker research, supporting multiple projects aimed at improving predictive assays like PD-L1 testing. Additionally, regulatory agencies such as the U.S. FDA and the European Medicines Agency (EMA) are encouraging biomarker-driven drug development, leading to increased adoption of PD-L1 testing in preclinical and clinical studies.

Based on the Region, Asia-Pacific emerged as the fastest growing region in the Global PD-L1 Biomarker Testing Market during the forecast period. This is due to the rising incidence of cancer, increasing adoption of immunotherapy, and growing investments in precision medicine. Countries like China, Japan, South Korea, and India are experiencing a surge in lung, bladder, and head & neck cancers, leading to a higher demand for PD-L1 testing as a companion diagnostic for immune checkpoint inhibitors. According to the World Health Organization (WHO), Asia accounts for nearly 50% of global cancer cases, highlighting the urgent need for advanced diagnostic solutions. Governments and healthcare organizations are actively promoting biomarker-driven treatments. For instance, China’s National Medical Products Administration (NMPA) has accelerated approvals for PD-L1-based assays to support immuno-oncology drugs. Similarly, Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) is fostering innovations in companion diagnostics to improve patient outcomes. The expansion of biopharmaceutical R&D hubs in Asia, coupled with rising collaborations between global diagnostic firms and regional healthcare providers, is further boosting market growth.

Moreover, the increasing availability of PD-L1 testing in hospitals and laboratories, improvements in healthcare infrastructure, and growing awareness about personalized cancer treatments are driving demand. As Asia-Pacific continues to evolve as a hub for oncology research and precision medicine, PD-L1 biomarker testing is expected to see significant expansion across the region.

Major companies operating in Global PD-L1 Biomarker Testing Market are:

• AstraZeneca PLC
• Merck Group (SigmaAldrich Co., LLC)
• F. Hoffmann-La Roche Ltd.
• Abcam
• Agilent technologies
• NeoGenomics Laboratories, Inc.
• ACROBiosystems
• PerkinElmer Inc.
• Guardant Health
• Quanterix

Download Free Sample Report

Customers can also request for 10% free customization on this report

“The Global PD-L1 Biomarker Testing Market is expanding due to the increasing focus on companion diagnostics by pharmaceutical companies to optimize immunotherapy treatments. With the rise of immune checkpoint inhibitors, drug developers are actively collaborating with diagnostic firms to create FDA-approved PD-L1 assays tailored to specific therapies. This synergy ensures that only patients most likely to benefit from these treatments receive them, improving clinical outcomes and reducing unnecessary healthcare costs. As regulatory agencies emphasize precision medicine, the demand for validated PD-L1 biomarker tests continues to rise, driving market growth.,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm. 

“PD-L1 Biomarker Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Cancer Type (NSCLC, Kidney Cancer, Melanoma, Head and Neck, Bladder Cancer, Others), By Assay Kit Type (PD-L1 22C3 IHC, PD-L1 28-8 IHC, PD-L1 SP263, PD-L1 SP142), By End Use (Research and Development, Diagnostics), By Region and Competition, 2020-2030F”, has evaluated the future growth potential of Global PD-L1 Biomarker Testing Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global PD-L1 Biomarker Testing Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: sales@techsciresearch.com

Website: www.techsciresearch.com